This supports the possibility that cancers can develop resistance to CXCR2 inhibition via the upregulation of HIF1A or MYC expression and suggest that combining drugs targeting CXCR2 and HIF1A or MYC may increase their therapeutic efficacy. The gene discussed is CXCR2; the disease is cancer.